MovDisordV3, PubMed, Corpus, bibRecord, 002976

Valproate-induced Parkinsonism in epilepsy patients.

Identifieur interne : 002976 ( PubMed/Corpus ); précédent : 002975; suivant : 002977

Valproate-induced Parkinsonism in epilepsy patients.

Auteurs : Dominic Jamora ; Shih-Hui Lim ; Andrew Pan ; Louis Tan ; Eng-King Tan

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.

RBID : pubmed:17115396

English descriptors

KwdEn :
- Adult, Anticonvulsants (adverse effects), Chi-Square Distribution, Epilepsy (drug therapy), Female, Humans, Male, Middle Aged, Parkinsonian Disorders (chemically induced), Valproic Acid (adverse effects).
MESH :
- chemical , adverse effects : Anticonvulsants, Valproic Acid.
- chemically induced : Parkinsonian Disorders.
- drug therapy : Epilepsy.
- Adult, Chi-Square Distribution, Female, Humans, Male, Middle Aged.

Abstract

We systematically examined 226 epilepsy patients in a tertiary-referral center and found 6 (5.04%) to have valproate-induced Parkinsonism. There was a significantly higher prevalence of patients with Parkinsonism in the group of patients treated with valproate compared to those who were on other antiepileptic drugs (6 [5.04%] of 119 vs. 0 [0%] of 107; chi2 = 5.54; P = 0.025). These six patients had been on valproate for more than 3 years (mean, 75.67 +/- 25.32 months) at an average dose of 750 +/- 273.86 mg/day. The valproate doses were decreased or discontinued with supplementation from another antiepileptic medication. The mean UPDRS motor score significantly improved from 10.67 +/- 5.1 to 4.75 +/- 2.75 (P < 0.05). There was no relapse of seizures. Clinicians working in tertiary-referral centers should have a high index of suspicion for valproate-induced Parkinsonism. Early recognition and switching into another antiepileptic medication may help reduce unnecessary suffering in these patients.

DOI: 10.1002/mds.21188
PubMed: 17115396

Links to Exploration step

pubmed:17115396

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Valproate-induced Parkinsonism in epilepsy patients.</title>
<author><name sortKey="Jamora, Dominic" sort="Jamora, Dominic" uniqKey="Jamora D" first="Dominic" last="Jamora">Dominic Jamora</name>
<affiliation><nlm:affiliation>Department of Neurology, National Neuroscience Institute, Singapore.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lim, Shih Hui" sort="Lim, Shih Hui" uniqKey="Lim S" first="Shih-Hui" last="Lim">Shih-Hui Lim</name>
</author>
<author><name sortKey="Pan, Andrew" sort="Pan, Andrew" uniqKey="Pan A" first="Andrew" last="Pan">Andrew Pan</name>
</author>
<author><name sortKey="Tan, Louis" sort="Tan, Louis" uniqKey="Tan L" first="Louis" last="Tan">Louis Tan</name>
</author>
<author><name sortKey="Tan, Eng King" sort="Tan, Eng King" uniqKey="Tan E" first="Eng-King" last="Tan">Eng-King Tan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="doi">10.1002/mds.21188</idno>
<idno type="RBID">pubmed:17115396</idno>
<idno type="pmid">17115396</idno>
<idno type="wicri:Area/PubMed/Corpus">002976</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Valproate-induced Parkinsonism in epilepsy patients.</title>
<author><name sortKey="Jamora, Dominic" sort="Jamora, Dominic" uniqKey="Jamora D" first="Dominic" last="Jamora">Dominic Jamora</name>
<affiliation><nlm:affiliation>Department of Neurology, National Neuroscience Institute, Singapore.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lim, Shih Hui" sort="Lim, Shih Hui" uniqKey="Lim S" first="Shih-Hui" last="Lim">Shih-Hui Lim</name>
</author>
<author><name sortKey="Pan, Andrew" sort="Pan, Andrew" uniqKey="Pan A" first="Andrew" last="Pan">Andrew Pan</name>
</author>
<author><name sortKey="Tan, Louis" sort="Tan, Louis" uniqKey="Tan L" first="Louis" last="Tan">Louis Tan</name>
</author>
<author><name sortKey="Tan, Eng King" sort="Tan, Eng King" uniqKey="Tan E" first="Eng-King" last="Tan">Eng-King Tan</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Anticonvulsants (adverse effects)</term>
<term>Chi-Square Distribution</term>
<term>Epilepsy (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Valproic Acid (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term>
<term>Valproic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epilepsy</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Chi-Square Distribution</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We systematically examined 226 epilepsy patients in a tertiary-referral center and found 6 (5.04%) to have valproate-induced Parkinsonism. There was a significantly higher prevalence of patients with Parkinsonism in the group of patients treated with valproate compared to those who were on other antiepileptic drugs (6 [5.04%] of 119 vs. 0 [0%] of 107; chi2 = 5.54; P = 0.025). These six patients had been on valproate for more than 3 years (mean, 75.67 +/- 25.32 months) at an average dose of 750 +/- 273.86 mg/day. The valproate doses were decreased or discontinued with supplementation from another antiepileptic medication. The mean UPDRS motor score significantly improved from 10.67 +/- 5.1 to 4.75 +/- 2.75 (P < 0.05). There was no relapse of seizures. Clinicians working in tertiary-referral centers should have a high index of suspicion for valproate-induced Parkinsonism. Early recognition and switching into another antiepileptic medication may help reduce unnecessary suffering in these patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17115396</PMID>
<DateCreated><Year>2007</Year>
<Month>01</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>04</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>22</Volume>
<Issue>1</Issue>
<PubDate><Year>2007</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Valproate-induced Parkinsonism in epilepsy patients.</ArticleTitle>
<Pagination><MedlinePgn>130-3</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We systematically examined 226 epilepsy patients in a tertiary-referral center and found 6 (5.04%) to have valproate-induced Parkinsonism. There was a significantly higher prevalence of patients with Parkinsonism in the group of patients treated with valproate compared to those who were on other antiepileptic drugs (6 [5.04%] of 119 vs. 0 [0%] of 107; chi2 = 5.54; P = 0.025). These six patients had been on valproate for more than 3 years (mean, 75.67 +/- 25.32 months) at an average dose of 750 +/- 273.86 mg/day. The valproate doses were decreased or discontinued with supplementation from another antiepileptic medication. The mean UPDRS motor score significantly improved from 10.67 +/- 5.1 to 4.75 +/- 2.75 (P < 0.05). There was no relapse of seizures. Clinicians working in tertiary-referral centers should have a high index of suspicion for valproate-induced Parkinsonism. Early recognition and switching into another antiepileptic medication may help reduce unnecessary suffering in these patients.</AbstractText>
<CopyrightInformation>Copyright 2006 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jamora</LastName>
<ForeName>Dominic</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, National Neuroscience Institute, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>Shih-Hui</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pan</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Louis</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Eng-King</ForeName>
<Initials>EK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber>
<NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2007 Jun 15;22(8):1211</RefSource>
<PMID Version="1">17443705</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.21188</ArticleId>
<ArticleId IdType="pubmed">17115396</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002976 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002976 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:17115396
   |texte=   Valproate-induced Parkinsonism in epilepsy patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:17115396" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Valproate-induced Parkinsonism in epilepsy patients.

Valproate-induced Parkinsonism in epilepsy patients.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki